Page last updated: 2024-11-01

nifedipine and Cognitive Decline

nifedipine has been researched along with Cognitive Decline in 2 studies

Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.

Research Excerpts

ExcerptRelevanceReference
"This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine."9.27Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. ( Adams, J; Aisen, P; Anastasios, O; Banzi, R; Börjesson-Hanson, A; Breuilh, L; Calais, G; Coen, R; Crawford, F; Cregg, F; Daly, L; de la Sayette, V; Dereeper, O; Devendeville, A; Franceschi, M; Frisoni, G; Gaynor, S; Hendrix, S; Howard, R; Kálmán, J; Kennelly, S; Kenny, RA; Konsta, A; Lavenu, I; Lawlor, B; Lucca, U; Molloy, DW; Mullan, M; Nemni, R; Nenopoulou, S; Nobili, F; O'Dwyer, S; Olde Rikkert, MGM; Pakaski, M; Pasquier, F; Riepe, MW; Segurado, R; Sénéchal, O; Sheikhi, A; Taekema, DG; Tsolaki, M; Tsolaki-Tagaraki, F; Verhey, FR; Walsh, C; Zanetti, O, 2018)
"This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine."5.27Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. ( Adams, J; Aisen, P; Anastasios, O; Banzi, R; Börjesson-Hanson, A; Breuilh, L; Calais, G; Coen, R; Crawford, F; Cregg, F; Daly, L; de la Sayette, V; Dereeper, O; Devendeville, A; Franceschi, M; Frisoni, G; Gaynor, S; Hendrix, S; Howard, R; Kálmán, J; Kennelly, S; Kenny, RA; Konsta, A; Lavenu, I; Lawlor, B; Lucca, U; Molloy, DW; Mullan, M; Nemni, R; Nenopoulou, S; Nobili, F; O'Dwyer, S; Olde Rikkert, MGM; Pakaski, M; Pasquier, F; Riepe, MW; Segurado, R; Sénéchal, O; Sheikhi, A; Taekema, DG; Tsolaki, M; Tsolaki-Tagaraki, F; Verhey, FR; Walsh, C; Zanetti, O, 2018)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Dyer, AH1
Murphy, C1
Segurado, R2
Lawlor, B2
Kennelly, SP1
Kennelly, S1
Olde Rikkert, MGM1
Howard, R1
Pasquier, F1
Börjesson-Hanson, A1
Tsolaki, M1
Lucca, U1
Molloy, DW1
Coen, R1
Riepe, MW1
Kálmán, J1
Kenny, RA1
Cregg, F1
O'Dwyer, S1
Walsh, C1
Adams, J1
Banzi, R1
Breuilh, L1
Daly, L1
Hendrix, S1
Aisen, P1
Gaynor, S1
Sheikhi, A1
Taekema, DG1
Verhey, FR1
Nemni, R1
Nobili, F1
Franceschi, M1
Frisoni, G1
Zanetti, O1
Konsta, A1
Anastasios, O1
Nenopoulou, S1
Tsolaki-Tagaraki, F1
Pakaski, M1
Dereeper, O1
de la Sayette, V1
Sénéchal, O1
Lavenu, I1
Devendeville, A1
Calais, G1
Crawford, F1
Mullan, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease[NCT02017340]Phase 3511 participants (Actual)Interventional2013-04-24Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

2 trials available for nifedipine and Cognitive Decline

ArticleYear
Is Ongoing Anticholinergic Burden Associated With Greater Cognitive Decline and Dementia Severity in Mild to Moderate Alzheimer's Disease?
    The journals of gerontology. Series A, Biological sciences and medical sciences, 2020, 04-17, Volume: 75, Issue:5

    Topics: Aged; Alzheimer Disease; Apolipoprotein E4; Cholinergic Antagonists; Cognitive Dysfunction; Disabili

2020
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
    PLoS medicine, 2018, Volume: 15, Issue:9

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Calcium Channel Blockers; Cognitive Dysfunction; Disease

2018